PHI-501

N/A

Report date: 2025/06/26 16:55:01
NME

Base Information

Drug NamePHI-501
Drug Alias NamePHI-501
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRAF serine/threonine protein kinase inhibitorsDiscoidin domain receptor 1 inhibitorsDiscoidin domain-containing receptor 2 inhibitors
TargetsRAF serine/threonine protein kinaseDiscoidin domain receptor 1Discoidin domain-containing receptor 2
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPharos iBio Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPharos iBio Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A